Literature DB >> 10940742

Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patients.

S Yano1, T Sugimoto, M Kanzawa, T Tsukamoto, T Hattori, S Hattori, K Chihara.   

Abstract

The present study was performed to investigate the association of calcium-sensing receptor (CaSR) genotypes with parathyroid hormone (PTH) secretion in hemodialysis patients. Subjects were 122 Japanese hemodialysis patients, including 39 patients with diabetes mellitus (DM). The CaSR polymorphisms tested were codon 990 in intracellular domain (A/A, A/G, and G/G groups) as well as T to C base change of intron 4 (T/T, T/C, and C/C groups). Statistical analysis of these polymorphisms revealed that the serum PTH level was significantly higher in the A/A group than in the G/G group in the former. In addition, the serum PTH level was also significantly higher in patients displaying C allele, as compared with the T/T group in the latter. This association of two polymorphisms with the serum PTH level was observed only in non-DM patients. Although two polymorphisms affected the PTH level independently, patients who possessed both genotypes (AAC+) had a markedly high level of PTH not only in the non-DM group but also in the DM group. The present findings indicate the possibility of the prediction for the extensive progression of secondary hyperparathyroidism through analyzing the CaSR polymorphisms in chronic hemodialysis patients. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940742     DOI: 10.1159/000045681

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Antilipolytic effect of calcimimetics depends on the allelic variant of calcium-sensing receptor gene polymorphism rs1042636 (Arg990Gly).

Authors:  Marcela Reyes; Hansjörg M Rothe; Pamela Mattar; Warren B Shapiro; Mariana Cifuentes
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

2.  Role of intron 5 C/T polymorphism of the calcium sensing receptor gene in the regulation of the serum FSH and LH in post-menopausal women.

Authors:  I Zofková; K Zajícková; M Hill; M Vanková
Journal:  J Endocrinol Invest       Date:  2005 Jul-Aug       Impact factor: 4.256

Review 3.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

4.  Association studies of calcium-sensing receptor (CaSR) polymorphisms with serum concentrations of glucose and phosphate, and vascular calcification in renal transplant recipients.

Authors:  Valerie N Babinsky; Fadil M Hannan; Sonia C Youhanna; Céline Maréchal; Michel Jadoul; Olivier Devuyst; Rajesh V Thakker
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

5.  Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients.

Authors:  Alicja E Grzegorzewska; Mateusz Paciorkowski; Adrianna Mostowska; Bartosz Frycz; Wojciech Warchoł; Ireneusz Stolarek; Marek Figlerowicz; Paweł P Jagodziński
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

6.  Genetic variants of calcium sensing receptor gene and risk of colorectal cancer: A case-control study.

Authors:  Ayat Badr Al-Ghafari
Journal:  Pak J Med Sci       Date:  2019 Mar-Apr       Impact factor: 1.088

7.  Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study.

Authors:  Alicja E Grzegorzewska; Bartosz A Frycz; Monika Świderska; Leszek Niepolski; Adrianna Mostowska; Paweł P Jagodziński
Journal:  BMC Nephrol       Date:  2019-11-27       Impact factor: 2.388

8.  Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Authors:  Sohyun Jeong; In-Wha Kim; Kook-Hwan Oh; Nayoung Han; Kwon Wook Joo; Hyo Jin Kim; Jung Mi Oh
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.